Galderma Shares Rise After Guidance Lift
By Maitane Sardon
Shares in Galderma jumped after the Swiss skincare company raised its full-year guidance following strong sales growth in the third quarter.
Shares were 5.5% higher at 144.00 Swiss francs in early European trade Thursday.
Galderma said sales in the third quarter rose 21% on year at constant currency, mainly thanks to strong performance of its Injectable Aesthetics and its Nemluvio dermatology portfolio.
It said it expects full-year sales to grow between 17% and 17.7% at constant currency, compared with previous estimates of between 12% and 14%. It sees the core earnings before interest, taxes, depreciation and amortization margin coming in between 23.1% and 23.6%, from 23% previously.
The new guidance suggests roughly 2% upside to sales and 5% upside to Ebitda versus current market expectations, RBC Capital Markets analysts said in a research note.
The slight margin increase reflects ongoing investment to drive growth across the group and the continued scaling of the dermatology treatment Nemluvio while also factoring in the impact of U.S. tariffs, the analysts said.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
October 23, 2025 04:37 ET (08:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States